Sumanta K. Pal, MD: Let's Get More Patients With Rare Tumors Into Clinical Trials
In My Opinion
Sumanta K. Pal, MD, of City of Hope, talks about the need for investigators across the country to enroll their patients with rare tumors in clinical trials. He describes a trial he is leading for papillary kidney cancer and how others can join his efforts.
Owen A. O'Connor, MD, PhD, of Columbia University Medical Center, shares his perspective on immunotherapy for patients with late-stage cancer in the context of a clinical trial set...
Allen S. Lichter, MD, Board Chair of the Value in Cancer Care Consortium, and Mark J. Ratain, MD, of the University of Chicago, discuss the benefits—and chal...
Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, discusses the benefits of decision support tools, especially for the oncologist who treats a variety of canc...
A. Oliver Sartor, MD, of Tulane University, speaks anecdotally about immunotherapy for prostate cancer and shares his experiences in speaking to patients with late-stage dise...
Karim Fizazi, MD, PhD, of Gustave Roussy, urges governments, insurers, and pharmaceutical companies to work together in order to find a way to make antican...
